Naji L, Dennis B, Rodrigues M, Bawor M, Hillmer A, Chawar C
Trials. 2024; 25(1):286.
PMID: 38678289
PMC: 11055220.
DOI: 10.1186/s13063-024-08104-x.
Lim J, Farhat I, Douros A, Panagiotoglou D
PLoS One. 2022; 17(3):e0266142.
PMID: 35358261
PMC: 8970369.
DOI: 10.1371/journal.pone.0266142.
Stancil S, Abdel-Rahman S, Wagner J
J Pediatr Pharmacol Ther. 2021; 26(7):675-695.
PMID: 34588931
PMC: 8475793.
DOI: 10.5863/1551-6776-26.7.675.
Woody G
Dela J Public Health. 2021; 3(4):42-44.
PMID: 34466930
PMC: 8389727.
DOI: 10.32481/djph.2017.08.010.
Bart G, Saxon A, Fiellin D, McNeely J, Muench J, Shanahan C
Addict Sci Clin Pract. 2020; 15(1):4.
PMID: 31948487
PMC: 6966783.
DOI: 10.1186/s13722-020-0180-2.
A call for consensus in defining efficacy in clinical trials for opioid addiction: combined results from a systematic review and qualitative study in patients receiving pharmacological assisted therapy for opioid use disorder.
Dennis B, Sanger N, Bawor M, Naji L, Plater C, Worster A
Trials. 2020; 21(1):30.
PMID: 31907000
PMC: 6945391.
DOI: 10.1186/s13063-019-3995-y.
Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine.
Makarenko I, Mazhnaya A, Marcus R, Pykalo I, Madden L, Filippovich S
J Subst Abuse Treat. 2018; 87:1-8.
PMID: 29471921
PMC: 5826566.
DOI: 10.1016/j.jsat.2018.01.007.
A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine.
Marcus R, Bojko M, Mazhnaya A, Makarenko I, Filippovych S, Dvoriak S
J Subst Abuse Treat. 2018; 86:86-93.
PMID: 29415856
PMC: 5808584.
DOI: 10.1016/j.jsat.2018.01.003.
Advances in the treatment of opioid use disorders.
Woody G
F1000Res. 2017; 6:87.
PMID: 28184294
PMC: 5288680.
DOI: 10.12688/f1000research.10184.1.
Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant.
Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M
Am J Drug Alcohol Abuse. 2016; 42(5):614-620.
PMID: 27436632
PMC: 5156574.
DOI: 10.1080/00952990.2016.1197231.
Naltrexone: A Pan-Addiction Treatment?.
Aboujaoude E, Salame W
CNS Drugs. 2016; 30(8):719-33.
PMID: 27401883
DOI: 10.1007/s40263-016-0373-0.
Antagonist Models for Relapse Prevention and Reducing HIV Risk.
Woody G, Krupitsky E, Zvartau E
J Neuroimmune Pharmacol. 2016; 11(3):401-7.
PMID: 26922659
DOI: 10.1007/s11481-016-9659-8.
Addiction Science: A Rationale and Tools for a Public Health Response to Drug Abuse.
Rawson R, Rieckmann T, Gust S
Public Health Rev. 2016; 35(2).
PMID: 26752803
PMC: 4704692.
DOI: 10.1007/BF03391705.
Impact of Chronic Pain on Treatment Prognosis for Patients with Opioid Use Disorder: A Systematic Review and Meta-analysis.
Dennis B, Bawor M, Naji L, Chan C, Varenbut J, Paul J
Subst Abuse. 2015; 9:59-80.
PMID: 26417202
PMC: 4573077.
DOI: 10.4137/SART.S30120.
Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?.
Nunes E, Krupitsky E, Ling W, Zummo J, Memisoglu A, Silverman B
J Addict Med. 2015; 9(3):238-43.
PMID: 25901451
PMC: 4450918.
DOI: 10.1097/ADM.0000000000000125.
The globalization of addiction research: capacity-building mechanisms and selected examples.
Rawson R, Woody G, Kresina T, Gust S
Harv Rev Psychiatry. 2015; 23(2):147-56.
PMID: 25747927
PMC: 4356020.
DOI: 10.1097/HRP.0000000000000067.
Antagonist models for treating persons with substance use disorders.
Woody G
Curr Psychiatry Rep. 2014; 16(10):489.
PMID: 25182514
DOI: 10.1007/s11920-014-0489-1.
Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.
Mannelli P, Wu L, Peindl K, Swartz M, Woody G
Drug Alcohol Depend. 2014; 138:83-8.
PMID: 24602363
PMC: 4017322.
DOI: 10.1016/j.drugalcdep.2014.02.002.
The feasibility of an intensive case management program for injection drug users on antiretroviral therapy in St. Petersburg, Russia.
Shaboltas A, Skochilov R, Brown L, Elharrar V, Kozlov A, Hoffman I
Harm Reduct J. 2013; 10:15.
PMID: 24006958
PMC: 3844607.
DOI: 10.1186/1477-7517-10-15.
Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia.
Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Tsoy M, Wahlgren V
Drug Alcohol Depend. 2013; 132(3):674-80.
PMID: 23683793
PMC: 3971535.
DOI: 10.1016/j.drugalcdep.2013.04.021.